Glaxosmithkline halts RSV trial after safety recommendation

A late-stage study of Glaxosmithkline’s respiratory syncytial virus vaccine in pregnant women has been put on pause, the company informs Reuters.

Photo: Dado Ruvic/REUTERS / X02714

British firm Glaxosmithkline (GSK) has paused a clinical study of its vaccine candidate against respiratory syncytial virus (RSV) due to a safety recommendation from an independent committee, as reported by news company Reuters.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs